D. E. Shaw & Co., Inc. Beyond Spring Inc. Transaction History

D. E. Shaw & Co., Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.06 - $1.81 $198,980 - $339,767	-187,717 Reduced 53.61%	162,426 $161,000
Q2 2022 Aug 15, 2022	SELL	$1.13 - $2.66 $1,126 - $2,652	-997 Reduced 0.28%	350,143 $504,000
Q1 2022 May 16, 2022	BUY	$1.68 - $5.01 $102,300 - $305,073	60,893 Added 20.98%	351,140 $773,000
Q4 2021 Feb 14, 2022	BUY	$4.02 - $16.84 $392,725 - $1.65 Million	97,693 Added 50.74%	290,247 $1.32 Million
Q3 2021 Nov 15, 2021	BUY	$9.26 - $31.31 $1.78 Million - $6.03 Million	192,554 New	192,554 $3.04 Million

Q1 2021 May 17, 2021	SELL	$10.61 - $15.77 $630,700 - $937,431	-59,444 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$10.21 - $17.31 $606,923 - $1.03 Million	59,444 New	59,444 $725,000

5.44M

30.3K

1.8K

Ticker BYSI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,928,900
Market Cap $95.4M
Description
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.